Cytokinetics, Incorporated $CYTK Stock Position Raised by Handelsbanken Fonder AB

Handelsbanken Fonder AB boosted its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 626.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 234,500 shares of the biopharmaceutical company’s stock after purchasing an additional 202,200 shares during the period. Handelsbanken Fonder AB owned 0.19% of Cytokinetics worth $12,888,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in CYTK. Thornburg Investment Management Inc. lifted its holdings in shares of Cytokinetics by 16.2% in the third quarter. Thornburg Investment Management Inc. now owns 84,719 shares of the biopharmaceutical company’s stock valued at $4,656,000 after purchasing an additional 11,840 shares in the last quarter. US Bancorp DE raised its position in Cytokinetics by 149.9% during the third quarter. US Bancorp DE now owns 4,308 shares of the biopharmaceutical company’s stock valued at $237,000 after buying an additional 2,584 shares during the period. TD Asset Management Inc raised its position in Cytokinetics by 23.4% during the third quarter. TD Asset Management Inc now owns 671,780 shares of the biopharmaceutical company’s stock valued at $36,921,000 after buying an additional 127,488 shares during the period. Dana Investment Advisors Inc. lifted its stake in Cytokinetics by 4.9% in the 3rd quarter. Dana Investment Advisors Inc. now owns 17,413 shares of the biopharmaceutical company’s stock worth $957,000 after acquiring an additional 811 shares in the last quarter. Finally, Intrust Bank NA acquired a new stake in Cytokinetics during the 3rd quarter worth about $250,000.

More Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Leerink Partners raised its price target from $83 to $84 and kept an “outperform” rating, signaling continued institutional confidence in the stock’s upside potential. Leerink Partners raise
• Positive Sentiment: HC Wainwright continues to rate CYTK a “Buy” with a $136 price target — an aggressive upside relative to current levels, which supports longer-term investor optimism despite near-term volatility. HC Wainwright coverage
• Positive Sentiment: Investor commentary pieces remain bullish (e.g., recent “Why Cytokinetics is a Buy” article), which can help sustain retail interest and buying momentum over time. Why CYTK is a buy
• Neutral Sentiment: Reported short-interest data for late February shows anomalous/zero values (0 shares, 0.0 days-to-cover) — likely a data/reporting issue, so it provides no clear signal about directional pressure.
• Negative Sentiment: Shares moved down after the company’s recent quarterly report missed EPS expectations and triggered a negative market reaction; coverage noted a sharp intraday decline following the results. Weak earnings coverage
• Negative Sentiment: HC Wainwright cut EPS forecasts across FY2026–FY2028 and several quarters (Q1–Q4 2026), materially lowering near‑term profitability expectations even as it held a buy rating — a factor pressuring valuation multiples today. HC Wainwright estimate changes

Insider Activity at Cytokinetics

In related news, Director Wendell Wierenga sold 20,000 shares of the company’s stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $66.14, for a total value of $1,322,800.00. Following the completion of the sale, the director directly owned 32,444 shares in the company, valued at approximately $2,145,846.16. This represents a 38.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Andrew Callos sold 15,000 shares of the stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $61.93, for a total transaction of $928,950.00. Following the transaction, the executive vice president directly owned 50,440 shares in the company, valued at $3,123,749.20. The trade was a 22.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 121,171 shares of company stock valued at $7,801,108. Insiders own 3.40% of the company’s stock.

Cytokinetics Stock Performance

NASDAQ:CYTK opened at $62.22 on Monday. The company has a market capitalization of $7.61 billion, a P/E ratio of -9.53 and a beta of 0.56. The stock’s 50 day moving average price is $64.20 and its 200 day moving average price is $58.91. Cytokinetics, Incorporated has a 52 week low of $29.31 and a 52 week high of $70.98.

Cytokinetics (NASDAQ:CYTK) last posted its earnings results on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.02). The business had revenue of $17.76 million for the quarter, compared to analysts’ expectations of $8.02 million. The firm’s revenue was up 4.9% on a year-over-year basis. During the same period in the previous year, the business earned ($1.26) EPS. As a group, sell-side analysts forecast that Cytokinetics, Incorporated will post -5.24 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on CYTK shares. Citizens Jmp lifted their target price on Cytokinetics from $88.00 to $96.00 and gave the company a “market outperform” rating in a research note on Wednesday, February 25th. Truist Financial raised their price target on shares of Cytokinetics from $84.00 to $92.00 and gave the stock a “buy” rating in a report on Tuesday, February 3rd. Jefferies Financial Group reaffirmed a “buy” rating and set a $90.00 price objective on shares of Cytokinetics in a research report on Friday, January 9th. JPMorgan Chase & Co. increased their target price on shares of Cytokinetics from $70.00 to $74.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 20th. Finally, Morgan Stanley set a $90.00 target price on shares of Cytokinetics in a research note on Thursday, January 8th. Seventeen investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $88.83.

Cytokinetics Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.